GlassScriptPhysician profile
Marek Robert Lupicki
NPI 1508967746
$7,640.63
in general payments reported to CMS, 2019-2025
50 companies · $992 in 2025
The $992 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $1,000 · 2021: $1,263 · 2022: $1,153 · 2023: $1,275 · 2024: $1,143 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,142.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,061.29 | 2021-2025 | |
| Glaxosmithkline, LLC. | $693.92 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $481.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.31 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $433.83 | 2019-2024 | Verquvo, Steglatro, Belsomra |
| Pfizer INC. | $293.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.01 | 2020-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $230.19 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $222.58 | 2020-2023 | Xarelto |
| Amgen INC. | $191.19 | 2021-2025 | Repatha, Otezla, Otezla |
| Collegium Pharmaceutical, INC. | $163.05 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $153.54 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $140.35 | 2021-2025 | Zoryve, Seglentis, Livalo |
| Allergan, INC. | $137.22 | 2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marek Lupicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.